Data Foundry

Drug recalls 2025

Atomoxetine Capsules — Class II drug recall D-0244-2025

Ongoing recall by Glenmark Pharmaceuticals Inc., USA, reported 2025-02-26, distributed nationwide. CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Recall numberD-0244-2025
Product typeDrug
ClassificationClass II
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmGlenmark Pharmaceuticals Inc., USA, Mahwah, NJ, United States
Recall initiated2025-01-29
Classified2025-02-20
Reported by FDA2025-02-26
DistributedNationwide (US)
Quantity58,368 bottles
Reason classescgmp, specification failure
NDC16714-0755, 16714-0755-01, 16714-0756, 16714-0756-01, 16714-0757, 16714-0757-01, 16714-0758, 16714-0758-01, 16714-0759, 16714-0759-01, 16714-0760, 16714-0760-01, 16714-0761, 16714-0761-01
Lot numbers19233270, 19233278, 19233285, 19233806, 19240954, 19241854
Expiration dates2025-07, 2025-08, 2026-02, 2026-04

Product

Atomoxetine Capsules, USP, 100 mg, 30 capsule bottles, Rx Only, Manufactured for: Northstar Rx LLC., Memphis, TN 38141, Manufactured by: Glenmark Pharmaceuticals Ltd., Goa, India, NDC 16714-761-01.

Reason for recall

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0244-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.